Andrew Huberman· PhD
So that the vaccine trials tended to focus more on younger people. It had some older people in it, but it didn't I if I had designed the trial, I what I would have argued for is to have uh the older population more represented because that's who was dying from COVID and then having the prevention of death or hospitalization is the primary endpoint.